• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Double Bond Pharmaceutical

0.12 SEK

+4.24 %

Less than 1K followers

DBP B

Spotlight Stock Market

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+4.24 %
+2.50 %
+6.96 %
-8.21 %
+3.36 %
-5.02 %
-68.46 %
-90.22 %
-95.78 %

Double Bond Pharmaceutical, DBP, is a pharmaceutical company. The company's business focus is on the treatment of cancer, infections and autoimmune diseases. The research is based on the company's proprietary drug-delivery technology. The products are sold under separate brands and product development collaborations take place with other players in the industry. The company is headquartered in Uppsala.

Read more
Market cap
27.41M SEK
Turnover
5.04K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
EPS and dividend
Financial calendar
27.8.
2026

Interim report Q2'26

All
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Regulatory press release25.05.2026 klo 15.45

DBP: Double Bond Pharmaceutical submits abstract with final RWE data for Temodex to the SNO Meeting in Philadelphia

Double Bond Pharmaceutical
Press release06.05.2026 klo 14.04

DBP: Double Bond Pharmaceutical's Abstract on Temodex Accepted for Presentation at EANS2026

Double Bond Pharmaceutical
Regulatory press release28.04.2026 klo 19.00

DBP: Double Bond Pharmaceutical Announces Final Survival Data from Extensive Temodex Study: 5.6-Month Survival Advantage Confirmed

Double Bond Pharmaceutical

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Regulatory press release26.03.2026 klo 08.30

DBP: Double Bond Pharmaceutical Collaborates with Karolinska Institutet in Stockholm for Advanced RWE Analysis of Temodex

Double Bond Pharmaceutical
Regulatory press release19.02.2026 klo 19.03

DBP: Double Bond Pharmaceutical Reports Preliminary Survival Data from Large-Scale Retrospective Study of Temodex

Double Bond Pharmaceutical
Regulatory press release12.02.2026 klo 19.00

DBP: Double Bond Pharmaceutical AB Signs Strategic Agreement for Landmark Clinical Study of Temodex® Based on Latest WHO Standards

Double Bond Pharmaceutical
Press release24.06.2025 klo 09.00

DBP: Double Bond Pharmaceutical Re-engages Global CRO Allucent to Accelerate Phase 1 Clinical Trial for Glioblastoma Candidate SI-053

Double Bond Pharmaceutical
Press release17.06.2025 klo 11.59

DBP: Double Bond Pharmaceutical International AB (publ) Qualifies New Swedish EU-GMP-Approved Supplier for Key Component of SI-053

Double Bond Pharmaceutical